Clinical study with Biotie's BTT1023 in primary sclerosing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding

Biotie Therapies Corp.          Stock Exchange Release    24 July 2014 at 3.15 p.m. Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with its vascular adhesion protein-1 (VAP-1) antibody, BTT1023, in primary sclerosing cholangitis (PSC). PSC is a chronic and progressive orphan fibrotic disease for which there are currently no approved therapeutic treatments. The study will be conducted in the UK and is expected to start recruiting patients by the end of 2014. The grant holder and Chief Investigator for the study, Professor David Adams Director of the National Institute for Health Research (NIHR) Biomedical Research Unit in Liver Disease and Centre for Liver Research at the University of Birmingham, UK, said "We have demonstrated that PSC is driven by aberrant lymphocyte homing and were the first to report a role for VAP-1 in mediating liver inflammation and fibrosis. We are delighted to have been awarded this peer-reviewed grant which will allow us to investigate whether blocking VAP-1 with BTT1023 can offer the first effective therapeutic option for this life- changing disease." The investigator-sponsored study will be an open label, single arm, multi-centre study enrolling 41 patients which will examine the efficacy, safety and pharmacokinetic properties of BTT1023 in patients with primary sclerosing choloangitis. The duration of drug treatment in the study is 11 weeks and the primary efficacy endpoint will be reduction of elevated levels of alkaline phosphatase, a blood biomarker of bile duct inflammation. This project was awarded by the NIHR Efficacy and Mechanism Evaluation (EME) Programme* and is funded and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Biotie retains full rights to BTT1023. Turku, 24 July 2014 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail: virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com ABOUT BTT1023 BTT1023 is a fully human monoclonal antibody that specifically binds to vascular adhesion protein-1 (VAP-1) and prevents inflammation. Biotie has previously demonstrated encouraging efficacy and safety for BTT1023 in early clinical studies in rheumatoid arthritis and psoriasis patients and in a range of preclinical models of inflammatory diseases, including COPD. More recently, Biotie has generated data indicating that VAP-1, in addition to its role in inflammatory diseases, has an important role in fibrotic diseases. These data, generated in collaboration with National Institute for Health Research Liver Biomedical Research Unit at the University of Birmingham, UK, reveal significant potential for BTT1023 in fibrotic diseases of the liver. About the Investigators The University of Birmingham delivers excellence in liver research and has access to a large, well-defined, cohort of patients with PSC. Professor Adams at Birmingham developed the concept of PSC as a disease driven by aberrant lymphocyte homing and first reported a role for VAP-1 in the liver in mediating liver inflammation and fibrosis. Together with Dr Gideon Hirschfield he runs the PSC translational programme in Birmingham from where patients will be recruited for the trial. About Primary sclerosing cholangitis PSC is an orphan disease featuring chronic and progressive inflammation of the liver and is characterised by bile duct fibrosis and progression to cirrhosis. It most commonly affects men of working age and more than 50% of patients require liver transplantation within 10-15 years of symptomatic presentation. In the later stages of the disease patients feel severely unwell, with abdominal pain, itching, jaundice, poor appetite, deep fatigue and signs of malnourishment and eventually liver failure and death. There are no currently approved drugs to treat PSC and there is a high unmet medical need for new treatment options. ABOUT BIOTIE Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease and for which Biotie holds exclusive, global rights. Biotie is actively developing its pipeline assets, including SYN120, a unique potent 5-HT6/5-HT2a dual antagonist for which Biotie initially expects to conduct a Phase 2 study in Parkinson's disease dementia that is largely funded by the Michael J Fox Foundation; nepicastat, a selective inhibitor of dopamine beta hydroxylase which is currently in a Phase 2 study, fully funded by NIDA, for treatment seeking cocaine addicts; and BTT1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 for which Biotie intends to conduct a Phase 2 study in primary sclerosing cholangitis, a rare fibrotic disease of the liver. Biotie's shares are listed on NASDAQ OMX Helsinki. *The EME Programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland and NISCHR in Wales and the HSC R&D Division, Public Health Agency in Northern Ireland. It is managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton [HUG#1836952]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 99

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 27

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 235

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 254

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 148

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 489

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

YouTube Shuts Down Tenet Media Channel Amid Legal Issues

Updated Category News Views 305

YouTube's Action Against Tenet Media Explained YouTube, which is part of Alphabet (NASDAQ: GOOGL), has made a significant move by shutting down the Tenet Media channel, along with four other channels managed by Lauren Chen. This decision comes in response to serious legal actions taken by the U.S. Department of Justice against certain individuals involved in money...

Continue Reading
Ardelyx Faces Class Action Lawsuit Amidst Investment Losses

Updated Category News Views 112

Important Update for Ardelyx Investors Regarding Class Action Pomerantz LLP has recently informed shareholders about a class action lawsuit involving Ardelyx, Inc. This lawsuit targets both the company and its key officers, alleging violations of federal securities laws. Investors who held Ardelyx securities during a specified timeframe should pay close attention to this...

Continue Reading
Derek Bryson Park: Innovator Transforming Finance Worldwide

Updated Category News Views 205

Celebrating Derek Bryson Park's Impact on Finance Derek Bryson Park has recently been highlighted by The Enterprise World Magazine as a key figure in the financial industry, a well-deserved recognition for his extensive and impactful career. With three decades of experience, Park continues to innovate in finance, public service, and global diplomacy. Pioneering Leadership...

Continue Reading
Understanding Currency Impacts in Global Trade Dynamics

Updated Category News Views 291

Understanding Currency Impacts in Global Trade Dynamics Scott Bessent, a noted figure in finance, is igniting conversations regarding tariffs and trade in recent discussions. All eyes on Wall Street are focused on how these changes influence market dynamics. Initially, any reduction in the U.S. trade deficit with other nations may seem like a significant win for the...

Continue Reading
Pennant Group Expands Its Operations with Recent Acquisition

Updated Category News Views 283

Pennant Group's Strategic Acquisition Announcement The Pennant Group, Inc. (NASDAQ: PNTG), a prominent holding company in the healthcare industry, recently achieved a significant milestone by acquiring specific operational assets from UnitedHealth Group Incorporated. This notable transaction was made possible due to UnitedHealth’s acquisition of Amedisys Inc., enabling...

Continue Reading